All In Biotech

Drug Trial Radar · NCT03960385

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Last checked: Nov 19, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,854

Actual

Start

Aug 1, 2017

Primary completion

Mar 1, 2020

Study completion Mar 1, 2020

Sponsor

Lead sponsor
Albert B. Sabin Vaccine InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pan American Health Organization; State of Parana/Health Department of Parana; Ministry of Health, Brazil; Centro de Estudos Augusto Leopoldo Ayrosa Galvão
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study seeks to assess the effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age, dose and municipality of residence in five municipalities of Paraná State. Specific objectives include: * To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases. * To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases according in the following age groups 15 to 18 and 19 to 27 years of age in the municipalities of Maringá, Foz de Iguaçu, Londrina, Sarandi and Paranaguá. * To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases in the following age groups 9 to 14 and 28 to 45 years of age in the municipality of Paranaguá.

Conditions

  • Dengue

Interventions

  • CYD-TDVBiological

    Dengue vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dengue symptomatic caseTime frame: Aug 2017 - March 2020

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Augusto Leopoldo Ayrosa Galvão Study Center

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.